Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

mAbs

Volumn 7, Issue 6, 2015, Pages 1205-1211

  Gatault, Philippe ^a,b   Brachet, Guillaume ^a,c,d   Ternant, David ^a,c,d   Degenne, Danielle ^a,c,d   Récipon, Guillaume ^a   Barbet, Christelle ^a   Gyan, Emmanuel ^a,c,d   Gouilleux Gruart, Valérie ^a,c,d   Bordes, Cécile ^e,f   Farrell, Alexandra ^c,d   Halimi, Jean Michel ^a,b   Watier, Hervé ^a,c,d  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b FHU SUPORT   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d CNRS   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f CNRS Bordeaux Segalen University   (France)

Author keywords

Eculizumab; Hemolytic uremic syndrome; Paroxysmal nocturnal hemoglobinuria; Pharmacokinetics; Thrombotic microangiopathy

Indexed keywords

COMPLEMENT COMPONENT C5; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT INHIBITION; CONCENTRATION AT STEADY-STATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG MONITORING; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAINTENANCE THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; WEIGHT REDUCTION; YOUNG ADULT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BODY WEIGHT; DOSE RESPONSE; HALF LIFE TIME; HEMOGLOBINURIA, PAROXYSMAL; MAINTENANCE CHEMOTHERAPY; METABOLIC CLEARANCE RATE; METABOLISM; PERSONALIZED MEDICINE; PILOT STUDY; PROCEDURES;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HALF-LIFE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PILOT PROJECTS; PRECISION MEDICINE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84954200437     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1086049     Document Type: Article

References (17)

1. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-401; PMID:9171898; http:// dx. doi. org/10. 1016/S0161-5890(96)00078-8
2. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Nat Biotechnol 2007; 25:1256-64; PMID:17989688; http://dx. doi. org/ 10. 1038/nbt1344
3. Burwick RM, Burwick NR, Feinberg BB. Eculizumab fails to inhibit generation of C5a in vivo. Blood 2014; 124:3502-3; PMID:25431478; http://dx. doi. org/ 10. 1182/blood-2014-07-589366
4. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 2006; 355:1233-43; PMID:16990386; http://dx. doi. org/10. 1056/NEJMoa061648
5. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K,. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome. N Engl J Med 2013; 368:2169-81; PMID:23738544; http://dx. doi. org/10. 1056/NEJMoa1208981
6. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162:62-73; PMID:23617322; http://dx. doi. org/ 10. 1111/bjh. 12347
7. Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014; 63:40-8; PMID:24021908; http://dx. doi. org/10. 1053/j. ajkd. 2013. 07. 011
8. Editor MBH. Health chiefs refuse to pay for lifesaving kidney treatment [Internet]. The Times. [cited 2014 Aug 3]. Available at: http://www. thetimes. co. uk/tto/ health/news/article3775905. ece
9. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, et al. Dynamics of complement activation in atypical HUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-26; PMID:25037630; http://dx. doi. org/10. 1182/blood-2014-02-558296
10. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, et al. Genetic Variants in C5 and Poor Response to Eculizumab. N Engl J Med 2014; 370:632-9; PMID:24521109; http://dx. doi. org/ 10. 1056/NEJMoa1311084
11. Ring T. Eculizumab in Atypical Hemolytic-Uremic Syndrome. N Engl J Med 2013; 369: 1377-80; PMID:24088106; http://dx. doi. org/10. 1056/NEJMc 1308826
12. Jaskowski TD, Martins TB, Litwin CM, Hill HR. Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol 1999; 6:137-9; PMID:9874678
13. Reiss U, Schwartz J, Sakamoto K, Puthenveetil G, Ogawa M, Bedrosian CL, Ware RE. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria: Eculizumab in Children with PNH. Pediatr Blood Cancer 2014; 61:1544-50; PMID:24777716; http://dx. doi. org/10. 1002/ pbc. 25068
14. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440-8; PMID:24853860; http://dx. doi. org/10. 1111/ jth. 12615
15. Delmas Y, Bordes C, Loirat C, Fremeaux-Bacchi V, Combe C. Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 2013; 6: 243-4; PMID:26019860; http://dx. doi. org/10. 1093/ckj/sfs185
16. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 2009; 36: 341-51; PMID:19578985; http://dx. doi. org/10. 1007/s10928-009-9125-9
17. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59; PMID:20818831; http://dx. doi. org/10. 2165/11535960-000000000-00000